by Jeremy Chrisp | Aug 14, 2019 | News
EpiAxis has appointed The Sage Group to lead the partnering program for its peptide candidates which modulate the epigenetic control of metastatic cancer. SYDNEY, AUSTRALIA, August 12, 2019 /EINPresswire.com/ — Following a strategic review of its clinical and...
by Jeremy Chrisp | Dec 2, 2018 | News
EpiAxis Therapeutics, a University of Canberra spin out company, has expanded its clinical trial program to include two additional recruitment centres for its Phase 1b metastatic breast cancer program. Those centres are open for patient recruitment at the Southern...
by Jeremy Chrisp | Oct 19, 2017 | News
EpiAxis Phase 1 FPI News Release
by Jeremy Chrisp | Nov 14, 2016 | News
MEDIA RELEASE
by Jeremy Chrisp | Apr 4, 2016 | Uncategorized
On the 1 February this year the ACT Government approved the establishment of Epi Axis Therapeutics. Epi Axis was established to commercialise the innovative therapy developed by University of Canberra Professor in Molecular and Cellular Biology Dr Sudha Rao that aims...
